Maze Therapeutics

On #WorldKidneyDay, we are pleased to introduce you to Maze's patient advisory committee (PAC), comprised of representatives and allies of the APOL1 #kidneydisease and chronic kidney disease (CKD) patient communities. This committee ensures that the voices of patients and care partners are at the center of everything we do as we work toward our mission as well as educate on the importance of genetic testing. Early detection and awareness are critical to protecting #kidneyhealth. Learn more about kidney disease and this year's World Kidney Day theme here: https://lnkd.in/fW-T8xB

This #InternationalWomensDay, we’re celebrating women who inspire one another and #AccelerateAction by advancing science and shaping culture. Some members of the Maze team have shared what it means to them to lead with purpose and create lasting impact in the work we do every day. To the women of Maze and women everywhere driving change, thank you for moving us all forward. #IWD2025

On #RareDiseaseDay, we recognize and draw attention to the challenges faced by those living with a rare diseases, and we stand with the #raredisease community in bringing awareness and seeking solutions to often overlooked or underserved conditions. At Maze, we are committed to leveraging our Compass platform to advance potential medicines for both common and rare patient populations. By utilizing genetic insights, in addition to our work in chronic #kidneydisease and APOL1 kidney disease, we are urgently developing potentially transformative treatments in rare diseases including #phenylketonuria (PKU) as well as focal segmental glomerulosclerosis (FSGS), a small subpopulation of the estimated one million patients with APOL1 kidney disease (AKD). Join us in supporting these communities and learning more about Rare Disease Day here: https://lnkd.in/gk6hbAF

At Maze, we recognize that innovation in medicine must go hand in hand with equity in access. This #BlackHistoryMonth, our director of patient advocacy and community engagement Danielle Branch, MBA, led a conversation about the important role patient advisory groups play as a resource for Black communities and patients. This is especially important to our work, as one of our disease focus areas primarily affects Black populations. Working closely with patient groups, we aim to drive meaningful change in how treatments are developed and delivered.

We're looking for a VP, Program Leader to drive the vision and execution of our SLC6A19 program. This is a critical leadership role, overseeing strategy, resources, and cross-functional collaboration to bring a potential new therapy to patients. If you have leadership experience in drug development and are ready to make an impact, we'd love to connect. Apply here: https://lnkd.in/gjX8PXyv #Biotech #DrugDevelopment #Leadership #Hiring #BiotechJobs

We're pleased to share findings from work published in Nature Portfolio's Nature Genetics, in partnership with our collaborators, to discover gene-metabolite associations and how they impact human traits and disease, including #kidneydisease. This work included studies to elucidate SLC6A19's role in kidney disease and informed the development of MZE782, designed to phenocopy the kidney protective effects of SLC6A19 protective variants. Now being advanced in a Phase 1 clinical trial, these findings further increase the genetic evidence for MZE782 to address a substantial number of patients with chronic kidney disease. Read the full paper here: https://lnkd.in/eWcUiPrf

This #LunarNewYear, our team came together to celebrate the Year of the Snake, a symbol of wisdom, transformation and resilience. As part of the event, Terrence Satterfield presented on the significance behind this zodiac year. We were also joined by Yannan Xi who spoke to the themes of resilience, adaptability, and perseverance and how we can honor these themes as we continue our work at Maze. Thank you to Terry and Yannan for the insightful conversation and to everyone who joined in the celebration. 

We are pleased to announce the first patient has been dosed in our Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 #kidneydisease (AKD). MZE829 is an oral, small molecule #APOL1 inhibitor that we are advancing as a potential treatment for people living with AKD, a subset of chronic kidney disease estimated to affect over one million patients in the U.S. alone. The HORIZON study is designed to include a broad spectrum of patients across multiple cohorts, reflecting the diverse characteristics of AKD. Read more here: https://lnkd.in/ekCE2nbg

❤️ Harnessing the power of genetics to transform the lives of patients. 🧬 Maze Therapeutics is committed to developing novel, small molecule precision medicines for individuals living with renal, cardiovascular and related metabolic diseases. 🔔 Congratulations on becoming #NasdaqListed, $MAZE!

We are excited to announce the pricing of our IPO and listing on Nasdaq as $MAZE. This milestone is a testament to the dedication of our incredible team, the trust of our partners, and the belief in our vision to make a lasting impact for patients. This exceptional progress from the team over the past several years marks the beginning of an exciting new chapter in our mission to harness the power of human genetics to transform the lives of patients. https://lnkd.in/eXTKUUkU